Handelsavisen
prelaunch
Companies ›Healthcare ›3151.T
31
3151.T — Tokyo Stock Exchange Pharmaceuticals

Vital Ksk Holdings Inc

¥1 555,00
Open in Charts → Attach watcher ⌖
— —
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,15 %
Op margin
0,9 %
ROE
6,9 %
Net margin
1,2 %
Debt / equity
0,08
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Vital Ksk Holdings Inc operates in the pharmaceuticals industry, focusing on drug development and medical research.

Business. Vital Ksk Holdings Inc (3151.T) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 3151.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 3151.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Vital Ksk Holdings Inc (3151.T) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Vital Ksk Holdings Inc maintains a strong liquidity position with a current ratio of 1.07 and cash and equivalents amounting to 23,099,000,000 JPY. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Despite a negative operating cash flow of -8,023,000,000 JPY, the firm generates positive free cash flow of 4,669,000,000 JPY, supporting operational flexibility.

    Profitability metrics show a return on equity of 6.9% and a return on assets of 2.44%. These figures are below the industry median for ROE and ROA, suggesting that Vital Ksk Holdings Inc is underperforming relative to its peers in terms of capital efficiency and asset utilization.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification may expose the firm to higher operational and market risks, particularly in the pharmaceuticals industry where regulatory and market dynamics can vary significantly by region.

    Looking ahead, Vital Ksk Holdings Inc is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The firm's capital expenditure of -4,337,000,000 JPY indicates a focus on cost management and asset optimization. However, the negative operating cash flow suggests potential challenges in converting operations into cash, which may require closer monitoring.

    Risk factors for the company are currently low, with no immediate liquidity or dilution concerns identified. The firm's low dilution potential and conservative capital structure reduce the likelihood of equity dilution in the near term. However, the negative operating cash flow could signal underlying operational inefficiencies that may need to be addressed.

    Recent financial filings and transcripts do not indicate any material events or strategic shifts for Vital Ksk Holdings Inc. The company appears to be maintaining a steady course, with no significant new product launches or market expansions disclosed in the available data.

    Key takeaways
    • Vital Ksk Holdings Inc maintains a conservative capital structure with a low debt-to-equity ratio of 0.08.
    • The company's return on equity of 6.9% is below the industry median, indicating suboptimal capital efficiency.
    • Revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
    • The firm generates positive free cash flow despite a negative operating cash flow, supporting operational flexibility.
    • No immediate liquidity or dilution risks are identified, but the negative operating cash flow warrants closer monitoring.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥1 555,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥105.91B
    Net cashⓘ
    ¥14.56B
    Current ratioⓘ
    1.1
    Debt / equityⓘ
    0.1
    ROAⓘ
    2.4%
    ROEⓘ
    6.9%
    Cash conversionⓘ
    -110.0%
    CapEx / revenueⓘ
    -0.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin0,9 %Below median
    Net Margin1,2 %Below median
    ROE6,9 %Above median
    Capex / Rev-0,7 %Above P75
    D/E0,08Above median
    Cash Conv-1,10Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Vital Ksk Holdings Inc Market data — financials · 2026-05-26
    • Vital Ksk Holdings Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    3151.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage